Cambrex history

1984: The pair purchase EDT Technology.

1986: CasChem continues its buying spree and purchases Nepera Inc.

With the 1987 acquisition of Wickhen Products, a manufacturer of cosmetic intermediaries, CasChem counted a total of six companies under its management.

1989: Humphrey Chemicals is acquired.

Salsbury Chemicals was purchased from Solvay's Animal Health division in 1991.

By the end of 1992, more than 25 percent of total sales for the Cambrex group of companies were outside the United States, with Germany and China as the firm's largest export customers.

In January 1994, Cambrex purchased Hexcel Corporation, located in Middlesbrough, England, for a little less than $10 million.

By 1995, Cambrex had become well-known within the specialty and fine chemicals industry as a successful international company.

The $130 million deal was "of significant strategic importance to Cambrex because it gives the company an immediate presence in a field widely considered one of the most promising pharmaceutical frontiers," wrote the Chemical Market Reporter in 1997.

One such purchase was the July 2000 acquisition of LumiTech Ltd., a supplier to the drug discovery market based in the United Kingdom.

Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales.

Cambrex entered the millennium intent on increasing its revenues related to its life science businesses to $1 billion by 2004.

In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group.

In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President.

To broaden their biocatalysis platform, Cambrex acquired IEP in 2010, now known as Cambrex IEP.

How has Cambrex Corporation performed financially from the 2013?

Investment continued at Charles City, IA with a 45,000 sq. ft temperature and humidity-controlled cGMP warehouse space in 2015.

Cambrex continued to invest in its sites in 2016.

In 2017, Cambrex invested in new small scale capacity at its Charles City, IA facility with the installation of two 500 gallon glass lined reactors and created a third small scale work center, further increasing flexibility for customer projects.

In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO. In late 2019, Cambrex was acquired by an affiliate of the Permira funds.